Adverse events · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amputation · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Total sleep time, next night; · Shift workers
1 finding from 1 review
no estimate extracted
1 study · 3 participants
Low
Sleep onset latency, next night; · Shift workers
1 finding from 1 review
no estimate extracted
1 study · 3 participants
Low
Sleep efficiency · Shift workers
1 finding from 1 review
no estimate extracted
1 study · 3 participants
Low
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Ulcer severity score (USS) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Beta-glucan (1.3/1.6 beta-glucan 10 mg twice daily for 20 days) led to lower ulcer severity score (USS) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Number of infants with a caries increment (dmfs) · Infants (primary teeth)
It is very uncertain whether xylitol tablets (200 to 600 mg/day) via slow-release pacifier/dummy changes number of infants with a caries increment (dmfs) compared with control (sorbitol) tablets (very low certainty).
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
One trial at high risk of bias compared clofazimine (n=23) with placebo (n=20). The number of individuals in the clofazimine group who had no further aphthous episodes from beginning treatment until completion at 6…
1 study · 43 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Clofazimine was associated with an increase in cutaneous adverse effects (skin pigmentation and drying) (Fisher's exact test P=0.015), but these were reported to be easily controlled.
1 study · 43 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · gabapentin with adjunctive ALA
SoF2 subgroup. Gabapentin + adjunctive ALA vs placebo forms one of two subgroups of the anticonvulsant symptom-relief estimate (RR 4.00, 2.09 to 7.67); no between-subgroup difference vs gabapentin alone; 100…
1 study · 40 participants
Very low
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Davies 1988 (aciclovir vs placebo, 36 patients, cross-over; high risk of reporting bias; concomitant treatments): data were not presented in a usable format; authors reported no statistically significant difference in…
1 study · 36 participants
GRADE not reported
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adjusted maximum ulcer size and adjusted maximum pain · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review